

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l20 and ph	1	<u>L21</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	6113946.pn. and (antigen\$ with peptide\$)	1	<u>L20</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l16 and mitochondria	21	<u>L19</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l16 and (oxidative with phosphorylation)	0	<u>L18</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l16 and (oxidative with phosphorylation) or mitochondria	3553	<u>L17</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	L15 same peptide\$	132	<u>L16</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	lysosom\$ same target\$	490	<u>L15</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l13 and lysosom\$	0	<u>L14</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l11 and ucp and antisense	1	<u>L13</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l11 and (ucp same antisense)	0	<u>L12</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	6187560.pn.	2	<u>L11</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l5 and (antisense or ribozyme\$)	11	<u>L10</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l5 and (nucleotide with analog\$)	1	<u>L9</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l5 and (nucleotide with analog\$)	1	<u>L8</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l5 same (nucleotide with analog\$)	0	<u>L7</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l5 same (nucleotide with analog\$)	0	<u>L6</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	ucp same inhibit\$	16	<u>L5</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	ucp same inhibit\$	16	<u>L4</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l2 with mechanism	3	<u>L3</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	dnp or (dinitro adj phenol)	1980	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	dnp or (dinitro adj phenol) same mechanism	1864	<u>L1</u>

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Terms	Documents
l2 with mechanism	3

Database: US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

l2 with mechanism

Clear**Search History****Today's Date: 7/9/2001**

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	l2 with mechanism	3	<u>L3</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	dnp or (dinitro adj phenol)	1980	<u>L2</u>
USPT,PGPB,JPAB,EPAB,DWPI,TDBD	dnp or (dinitro adj phenol) same mechanism	1864	<u>L1</u>

et	Items	Description
S1	400	TUNICAMYCIN (S) (T (W) CELL?)
S2	3	S1 AND NEUTROPHIL?
S3	3	RD (unique items)
S4	10	UCP (W) INHIBIT?
S5	3	RD (unique items)

>>>KWIC option is not available in file(s): 41, 77, 399

5/3,K/1 (Item 1 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2002 BIOSIS. All rts. reserv.

09304552 BIOSIS NO.: 199497312922
A sequence related to a DNA recognition element is essential for the inhibition by nucleotides of proton transport through the mitochondrial uncoupling protein.
 AUTHOR: Bouillaud F(a); Arechaga I; Petit P X; Raimbault S; Levi-Meyrueis C ; Casteilla L; Laurent M; Rial E; Ricquier D
 AUTHOR ADDRESS: (a)Centre de Recherches sur l'Endocrinologie Moleculaire le Developpment, CNRS, 9 rue Jules Hetzel,**France
 JOURNAL: EMBO (European Molecular Biology Organization) Journal 13 (8):p 1990-1997 1994
 ISSN: 0261-4189
 DOCUMENT TYPE: Article
 RECORD TYPE: Abstract
 LANGUAGE: English

...ABSTRACT: from ATP production by introducing a proton conducting pathway through the mitochondrial inner membrane. The activity of the UCP is regulated: nucleotide binding to the *UCP* *inhibits* proton conductance whereas free fatty acids increase it. The similarities between the UCP, the ADP/ATP carrier and the DNA recognition element found in the...

5/3,K/2 (Item 1 from file: 357)
 DIALOG(R)File 357:Derwent Biotech Res
 (c) 2002 Thomson Derwent & ISI. All rts. reserv.

0265635 DBA Accession No.: 2001-05389 PATENT
Inhibiting plasma membrane uncoupling protein expression in tumor cells and rapidly dividing bacterial cells, for treating cancer and infectious diseases - uncoupling protein-inhibitor drug screening for chemotherapy sensitization of tumor cell
 AUTHOR: Newell M K
 CORPORATE SOURCE: Burlington, VT, USA.
 PATENT ASSIGNEE: Univ.Vermont 2000
 PATENT NUMBER: WO 200078941 PATENT DATE: 20001228 WPI ACCESSION NO.: 2001-102716 (2011)
 PRIORITY APPLIC. NO.: US 140574 APPLIC. DATE: 19990623
 NATIONAL APPLIC. NO.: WO 2000US17245 APPLIC. DATE: 20000622
 LANGUAGE: English

ABSTRACT: Inhibiting plasma membrane uncoupling protein (UCP) expression in a cell, comprises contacting a cell with a plasma membrane *UCP*-inhibitor*. Also new are: a composition of a plasma membrane targeted *UCP*-inhibitor* ; sensitizing a resistant tumor cell to a cytotoxic therapy by expressing a functional UCP or UCP fragment in a plasma membrane of a resistant tumor...

... arrested cell; regulating lysosomal pH by modifying lysosomal UCP activity in a cell; treatment of autoimmune disease by administering UCP activator; a composition of a *UCP*-inhibitor* ; therapy or prevention of infection using a *UCP*-inhibitor* ; nucleic acids encoding UCP; and transgenic animals and cells transfected with UCP. (106pp)

5/3,K/3 (Item 1 from file: 399)
 DIALOG(R)File 399:CA SEARCH(R)

(c) 2002 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

135285935 CA: 135(20)285935z PATENT

Transgenic plant expression uncoupling protein (UCP) for metabolism regulation

INVENTOR(AUTHOR): Berry-lowe, Sandra Lee; Newell, Martha Karen

LOCATION: USA

ASSIGNEE: University Technology Corporation

PATENT: PCT International ; WO 200175131 A2 DATE: 20011011

APPLICATION: WO 2001US10236 (20010330) *US PV193533 (20000331)

PAGES: 72 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/82A;
C12N-015/63B; A01H-001/00B; A01H-005/10B DESIGNATED COUNTRIES: AE; AG; AL;
AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK;
DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG;
KP; KR; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ;
PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN;
YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM
; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI;
FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN;
GW; ML; MR; NE; SN; TD; TG

?

Set	Items	Description
S1	400	TUNICAMYCIN (S) (T (W) CELL?)
S2	3	S1 AND NEUTROPHIL?
S3	3	RD (unique items)

>>>KWIC option is not available in file(s): 41, 77, 399

3/3,K/1 (Item 1 from file: 34)
 DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
 (c) 2002 Inst for Sci Info. All rts. reserv.

01269777 Genuine Article#: GJ941 No. References: 27
Title: STRUCTURE-FUNCTION RELATIONSHIP AND IMMUNOCHEMICAL MAPPING OF EXTERNAL AND INTRACELLULAR ANTIGENIC SITES ON THE LYMPHOCYTE-ACTIVATION INDUCER MOLECULE, AIM/CD69
 Author(s): SANCHEZMATEOS P; SANCHEZMADRID F
 Corporate Source: UNIV AUTONOMA MADRID,HOSP PRINCESA,SERV IMMUNOL,DIEGO LEON/E-28006 MADRID//SPAIN//; UNIV AUTONOMA MADRID,HOSP PRINCESA,SERV IMMUNOL,DIEGO LEON/E-28006 MADRID//SPAIN/
 Journal: EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, V21, N10, P2317-2325
 Language: ENGLISH Document Type: ARTICLE (Abstract Available)

...Abstract: highly conserved interspecies. Site E1 is shown to be an immunodominant antigenic determinant closely related to a functional domain of AIM important for triggering of *T* *cell* proliferation. Studies of peptide fragmentation of the two isolated AIM subunits with different proteases have demonstrated that both AIM chains are differentially glycosylated forms of...

...26 kDa which arise from the 24-kDa unglycosylated AIM polypeptide. This 24-kDa unglycosylated form could be also precipitated from iodinated cells pretreated with *tunicamycin*, indicating that glycosylation of the protein was neither required for AIM cell surface expression nor for acquisition of external epitopes E1-E3. Cell treatment with...
 Research Fronts: 89-0312 001 (TUMOR NECROSIS FACTOR; ANTIVIRAL ACTIVITY; EFFECTS OF CYTOKINES)
 89-0855 001 (LEUKOCYTE ADHESION DEFICIENCY; *NEUTROPHIL* ADHERENCE RECEPTOR; EXPRESSION OF LFA-1)
 89-2507 001 (INTERLEUKIN-2 RECEPTOR; GROWTH SIGNAL TRANSDUCTION; DECREASED EXPRESSION)
 89-3122 001 (T-CELL ACTIVATION; CD2 ANTIGEN...

3/3,K/2 (Item 1 from file: 370)
 DIALOG(R)File 370:Science
 (c) 1999 AAAS. All rts. reserv.

00501373 (USE 9 FOR FULLTEXT)
Engineering Chemical Reactivity on Cell Surfaces Through Oligosaccharide Biosynthesis
 Mahal, Lara K.; Yarema, Kevin J.; Bertozzi, Carolyn R.
 Department of Chemistry, University of California, Berkeley and Center for Advanced Materials, Materials Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.
 Science Vol. 276 5315 pp. 1125
 Publication Date: 5-16-1997 (970516) Publication Year: 1997
 Document Type: Journal ISSN: 0036-8075
 Language: English
 Section Heading: Reports
 Word Count: 2188

(THIS IS THE FULLTEXT)

...Text: the ketone functionality at the position normally occupied by the N-acetyl group in the natural substrate ManNAc. We selected three human cell lines-Jurkat (*T* *cell*-derived), HL-60 (*neutrophil*-derived), and HeLa (cervical epithelial carcinoma)-to test the biosynthetic conversion of ManLev to the corresponding cell surface-associated, unnatural sialic acid

(Fig. 1A). Cells...

...of experiments to demonstrate that the ketone groups are displayed on the cell surface in the form of modified sialoglycoconjugates. Jurkat cells were treated with *tunicamycin*, an inhibitor of N-linked protein glycosylation, before incubation with ManLev (B16) (B17) . We anticipated a dramatic reduction in ketone expression on the basis of...

...oligosaccharides on Jurkat cells are found on N-linked rather than O-linked glycoproteins (B18) . Indeed, ketone expression resulting from ManLev treatment was inhibited by *tunicamycin* in a dose-dependent fashion (Fig. 3A), suggesting that the ketone groups are presented on oligosaccharides and are not nonspecifically associated with cell surface components. In contrast, ketone expression in HL-60 and HeLa cells was unaffected by *tunicamycin*, but was instead blocked by a-benzyl N-acetylgalactosamine, an inhibitor of O-linked glycosylation, consistent with the high expression of mucin-like molecules on...Figure Removed

Figure F3

Caption: Ketone groups are expressed within cell surface sialic acids. (A) *Tunicamycin* inhibits ketone incorporation in a dose-dependent fashion, confirming the presence of ketones on N-linked oligosaccharides (B17) . Identical results were obtained in three replicate...

3/3,K/3 (Item 1 from file: 442)
DIALOG(R) File 442:AMA Journals
(c)2002 Amer Med Assn -FARS/DARS apply. All rts. reserv.

00036699

Copyright (C) 1983 American Medical Association

Chronic Lymphocytic Leukemia With IgM lambda and IgG lambda Cytoplasmic Inclusions (ORIGINAL ARTICLE)

WHITE, VALERIE

Archives of Pathology and Laboratory Medicine

November, 1983; 107: 580-582

LINE COUNT: 00140

WORD COUNT: 01942

... lymphadenopathy in cervical, axillary, and inguinal regions, as well as moderate hepatosplenomegaly. Laboratory tests produced the following values: WBC, 51,800/cu mm with 4% *neutrophils*, 1% monocytes, and 95% lymphocytes. Wright's stain showed that 86% of the lymphocytes contained intracytoplasmic inclusions measuring 1 to 3 mum in diameter (Fig...

...of chlorambucil without recurrent lymphadenopathy of hepatosplenomegaly. At the time of this study (February 1982), his WBC count was 23,000/cu mm with 9% *neutrophils*, 1% monocytes, 1% eosinophils, and 89% lymphocytes. The platelet count was 172,000/cu mm and the hemoglobin level was 11.8 g/dL. The...

CITED REFERENCES:

- ...T, Juritani T, et al: In vitro induction of IgM secretion and switching to IgG production in human B-leukemic cells with the help of *T*-*cells*. J Immunol 1980; 124: 2609-2614.
17. Fu SM, Chiorazzi N, Kunkel HG, et al: Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B-lymphocytes. J Exp Med 1978; 148: 1570-1578.
18. Chiorazzi N, Fu SM, Montazeri G, et al: *T*-*cell* helper defect in patients with chronic lymphocytic leukemia. J Immunol 1979; 122: 1087-1090.
19. Hickman S, Kornfeld S: Effect of *tunicamycin* on IgM, IgA, and IgG secretion by mouse plasmacytoma cells. J Immunol 1978; 121: 990-996.
20. Sibley CH, Wagner RA: Glycosylation is not required...

File 5: Biosis Previews(R) 1969-2002/Apr W1
 (c) 2002 BIOSIS
 File 6: NTIS 1964-2002/Apr W4
 (c) 2002 NTIS, Intl Cpyrght All Rights Res
 File 8: Ei Compendex(R) 1970-2002/Apr W2
 (c) 2002 Engineering Info. Inc.
 File 34: SciSearch(R) Cited Ref Sci 1990-2002/Apr W3
 (c) 2002 Inst for Sci Info
 File 65: Inside Conferences 1993-2002/Apr W2
 (c) 2002 BLDSC all rts. reserv.
 File 71: ELSEVIER BIOBASE 1994-2002/Apr W2
 (c) 2002 Elsevier Science B.V.
 File 73: EMBASE 1974-2002/Apr W2
 (c) 2002 Elsevier Science B.V.
 File 76: Life Sciences Collection 1982-2002/Apr
 (c) 2002 Cambridge Sci Abs
 File 94: JICST-EPlus 1985-2002/Mar W1
 (c) 2002 Japan Science and Tech Corp(JST)
 File 98: General Sci Abs/Full-Text 1984-2002/Mar
 (c) 2002 The HW Wilson Co.
 File 99: Wilson Appl. Sci & Tech Abs 1983-2002/Mar
 (c) 2002 The HW Wilson Co.
 File 135: NewsRx Weekly Reports 1995-2002/Mar W5
 (c) 2002 NewsRx
 File 143: Biol. & Agric. Index 1983-2002/Mar
 (c) 2002 The HW Wilson Co
 File 144: Pascal 1973-2002/Apr W2
 (c) 2002 INIST/CNRS
 File 155: MEDLINE(R) 1966-2002/Apr W2
 File 172: EMBASE Alert 2002/Apr W2
 (c) 2002 Elsevier Science B.V.
 File 266: FEDRIP 2002/Feb
 Comp & dist by NTIS, Intl Copyright All Rights Res
 File 315: ChemEng & Biotech Abs 1970-2002/Dec
 (c) 2002 DECHEMA
 File 357: Derwent Biotech Res 1982-2002/Feb w3
 (c) 2002 Thomson Derwent & ISI
 File 358: Current BioTech Abs 1983-2001/Oct
 (c) 2001 DECHEMA
 File 369: New Scientist 1994-2002/Apr W1
 (c) 2002 Reed Business Information Ltd.
 File 370: Science 1996-1999/Jul W3
 (c) 1999 AAAS
 File 399: CA SEARCH(R) 1967-2002/UD=13616
 (c) 2002 AMERICAN CHEMICAL SOCIETY
 File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 1998 Inst for Sci Info
 File 40: Enviroline(R) 1975-2002/Mar
 (c) 2002 Congressional Information Service
 File 41: Pollution Abs 1970-2002/May
 (c) 2002 Cambridge Scientific Abstracts
 File 50: CAB Abstracts 1972-2002/Mar
 (c) 2002 CAB International
 File 68: Env. Bib. 1974-2002/Mar
 (c) 2002 Internl Academy at Santa Barbara
 File 77: Conference Papers Index 1973-2002/Mar
 (c) 2002 Cambridge Sci Abs
 File 103: Energy SciTec 1974-2002/Mar B1
 (c) 2002 Contains copyrighted material
 File 156: ToxFile 1966-2002/Feb W4
 (c) 2002
 File 162: CAB HEALTH 1983-2002/Mar
 (c) 2002 CAB INTERNATIONAL
 File 305: Analytical Abstracts 1980-2002/Mar W4
 (c) 2002 Royal Soc Chemistry
 File 35: Dissertation Abs Online 1861-2002/Apr
 (c) 2002 ProQuest Info&Learning
 File 48: SPORTDiscus 1962-2002/May

(c) 2002 Sport Information Resource Centre
 File 91:MANTIS(TM) 1880-2002/Apr
 2001 (c) Action Potential
 File 149:TGG Health&Wellness DB(SM) 1976-2002/Apr W1
 (c) 2002 The Gale Group
 File 159:Cancerlit 1975-2002/Mar
 (c) format only 2002 Dialog Corporation
 File 164:Allied & Complementary Medicine 1984-2002/May
 (c) 2002 BLHCIS
 File 442:AMA Journals 1982-2002/Apr B1
 (c)2002 Amer Med Assn -FARS/DARS apply
 File 444:New England Journal of Med. 1985-2002/Apr W3
 (c) 2002 Mass. Med. Soc.
 File 457:The Lancet 1986-2000/Oct W1
 (c) 2000 The Lancet, Ltd.
 File 467:ExtraMED(tm) 2000/Dec
 (c) 2001 Informania Ltd.

Set	Items	Description
S1	400	TUNICAMYCIN (S) (T (W) CELL?)
S2	3	S1 AND NEUTROPHIL?
S3	3	RD (unique items)
S4	10	UCP (W) INHIBIT?
S5	3	RD (unique items)

...completed examining reco.

S5 16 RD (unique items)
?show files;ds;t/3,k/all
File 5: Biosis Previews(R) 1969-2002/Dec W5
(c) 2002 BIOSIS
File 6: NTIS 1964-2003/Jan W1
(c) 2003 NTIS, Intl Cpyrght All Rights Res
File 34: SciSearch(R) Cited Ref Sci 1990-2002/Dec W5
(c) 2002 Inst for Sci Info
File 40: Enviroline(R) 1975-2002/Dec
File 50: CAB Abstracts 1972-2002/Nov
(c) 2002 CAB International
File 65: Inside Conferences 1993-2003/Jan W1
(c) 2003 BLDSC all rts. reserv.
File 68: Env.Bib. 1972-2002/Jun
(c) 2002 Internl Academy at Santa Barbara
File 71: ELSEVIER BIOBASE 1994-2003/Jan W1
(c) 2003 Elsevier Science B.V.
File 73: EMBASE 1974-2003/Dec W5
(c) 2003 Elsevier Science B.V.
File 94: JICST-EPlus 1985-2003/Oct W4
(c) 2003 Japan Science and Tech Corp(JST)
File 98: General Sci Abs/Full-Text 1984-2002/Nov
(c) 2002 The HW Wilson Co.
File 103: Energy SciTec 1974-2002/Dec B2
(c) 2002 Contains copyrighted material
File 143: Biol. & Agric. Index 1983-2002/Nov
(c) 2002 The HW Wilson Co
File 144: Pascal 1973-2002/Dec W4
(c) 2002 INIST/CNRS
File 155: MEDLINE(R) 1966-2002/Dec W5
File 156: ToxFile 1965-2002/Nov W3
(c) format only 2002 The Dialog Corporation
File 162: CAB Health 1983-2002/Nov
(c) 2002 CAB International
File 172: EMBASE Alert 2003/Jan W1
(c) 2003 Elsevier Science B.V.
File 305: Analytical Abstracts 1980-2002/Dec W2
(c) 2002 Royal Soc Chemistry
File 369: New Scientist 1994-2003/Dec W4
(c) 2003 Reed Business Information Ltd.
File 370: Science 1996-1999/Jul W3
(c) 1999 AAAS
File 399: CA SEARCH(R) 1967-2003/UD=13802
(c) 2003 American Chemical Society
File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info
File 8: Ei Compendex(R) 1970-2003/Dec W5
(c) 2003 Elsevier Eng. Info. Inc.
File 99: Wilson Appl. Sci & Tech Abs 1983-2002/Nov
(c) 2002 The HW Wilson Co.
File 135: NewsRx Weekly Reports 1995-2003/Dec W5
(c) 2003 NewsRx
File 266: FEDRIP 2002/Nov
Comp & dist by NTIS, Intl Copyright All Rights Res
File 315: ChemEng & Biotec Abs 1970-2003/Dec
(c) 2003 DECHEMA
File 357: Derwent Biotech Res. 1982-2003/Dec W5
(c) 2003 Thomson Derwent & ISI
File 358: Current BioTech Abs 1983-2003/Dec
(c) 2003 DECHEMA
File 35: Dissertation Abs Online 1861-2003/Dec
(c) 2003 ProQuest Info&Learning
File 48: SPORTDiscus 1962-2002/Dec
(c) 2002 Sport Information Resource Centre
File 91: MANTIS(TM) 1880-2002/Oct
2002 (c) Action Potential

File 149:TGG Health&Wellness DB(SM) 1976-2003/Dec W4
(c) 2003 The Gale Group
File 159:Cancerlit 1975-2002/Oct
(c) format only 2002 Dialog Corporation
File 164:Allied & Complementary Medicine 1984-2002/Dec
(c) 2002 BLHCIS
File 442:AMA Journals 1982-2003/Feb B1
(c)2003 Amer Med Assn -FARS/DARS apply
File 444:New England Journal of Med. 1985-2003/Jan W1
(c) 2003 Mass. Med. Soc.
File 467:ExtraMED(tm) 2000/Dec
(c) 2001 Informania Ltd.

Set	Items	Description
S1	9073	(UNCOUPLING PROTEIN?) OR UCP OR UCP2
S2	5	S1 (S) LYSOSOM?
S3	3	RD (unique items)
S4	22	S1 AND LYSOSOM?
S5	16	RD (unique items)

Set	Items	Description
S1	9073	(UNCOUPLING PROTEIN?) OR UCP OR UCP2
S2	5	S1 (S) LYSOSOM?
S3	3	RD (unique items)

>>>KWIC option is not available in file(s): 399

3/3,K/1 (Item 1 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2002 BIOSIS. All rts. reserv.

09327235 BIOSIS NO.: 199497335605

Temperature and phenylmethylsulfonyl fluoride sensitive loss of uncoupling protein in isolated brown adipose tissue mitochondrial membranes.

AUTHOR: Desautels M; Dulos R A

AUTHOR ADDRESS: Dep. Physiol., Coll. Med., Univ. Saskatchewan, Saskatoon, SK S7N 0W0**Canada

JOURNAL: Biochemistry and Cell Biology 72 (1-2):p1-7 1994

ISSN: 0829-8211

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

SUMMARY LANGUAGE: English; French

ABSTRACT: When a membrane suspension prepared from isolated rat brown fat mitochondria was incubated at 37 degree C for 4 h, a loss of uncoupling protein (*UCP*) immunoreactivity was observed on Western blots. Analysis of (3H)GDP-binding characteristics to *UCP* in isolated membranes also showed a significant reduction in B-max without significant effect on K-d. The loss of *UCP* was not due to protease contamination from *lysosomes* or mast cell granules, since loss of *UCP* was still observed when mitochondria were treated with digitonin to lyse *lysosomes* prior to membrane preparation and when mitochondria were isolated from rats injected with compound 48/80 to degranulate mast cells. Furthermore, loss of *UCP* was observed at alkaline pH and was not affected by inhibitors of *lysosomal* enzymes. Loss of *UCP* immunoreactivity was markedly reduced when membranes were incubated at 4 degree C or in the presence of phenylmethylsulfonyl fluoride, but was not influenced by the...

...of GDP. Overall, these results indicate the presence of a serine protease within brown fat mitochondrial membranes that may be involved in the breakdown of *UCP*.

3/3,K/2 (Item 1 from file: 399)
 DIALOG(R)File 399:CA SEARCH(R)
 (c) 2003 American Chemical Society. All rts. reserv.

137260580 CA: 137(18)260580h JOURNAL
Differentiation-dependent expression of cathepsin D and importance of lysosomal proteolysis in the degradation of UCP1 in brown adipocytes

AUTHOR(S): Moazed, Banafsheh; Desautels, M.

LOCATION: College of Medicine, Department of Physiology, University of Saskatchewan, Saskatoon, SK, Can., S7N 5E5

JOURNAL: Can. J. Physiol. Pharmacol. (Canadian Journal of Physiology and Pharmacology) DATE: 2002 VOLUME: 80 NUMBER: 6 PAGES: 515-525 CODEN: CJPPA3 ISSN: 0008-4212 LANGUAGE: English PUBLISHER: National Research Council of Canada

3/3,K/3 (Item 1 from file: 357)
 DIALOG(R)File 357:Derwent Biotech Res.
 (c) 2003 Thomson Derwent & ISI. All rts. reserv.

0265635 DBR Accession No.: 2001-05389 PATENT

Inhibiting plasma membrane uncoupling protein expression in tumor cells and rapidly dividing bacterial cells, for treating cancer and infectious diseases - uncoupling protein-inhibitor drug screening for chemotherapy

sensitization of tumor cell

AUTHOR: Newell M K

CORPORATE SOURCE: Burlington, VT, USA.

PATENT ASSIGNEE: Univ.Vermont 2000

PATENT NUMBER: WO 200078941 PATENT DATE: 20001228 WPI ACCESSION NO.:
2001-102716 (2011)

PRIORITY APPLIC. NO.: US 140574 APPLIC. DATE: 19990623

NATIONAL APPLIC. NO.: WO 2000US17245 APPLIC. DATE: 20000622

LANGUAGE: English

ABSTRACT: Inhibiting plasma membrane uncoupling protein (*UCP*) expression in a cell, comprises contacting a cell with a plasma membrane *UCP* -inhibitor. Also new are: a composition of a plasma membrane targeted *UCP* -inhibitor; sensitizing a resistant tumor cell to a cytotoxic therapy by expressing a functional *UCP* or *UCP* fragment in a plasma membrane of a resistant tumor cell to sensitize the resistant tumor cell to a cytotoxic therapeutic; screening a tumor cell for...
... for screening a tumor cell or a subject for susceptibility to treatment with a chemotherapeutic agent; inducing cellular division in a growth arrested cell; regulating *lysosomal* pH by modifying *lysosomal* *UCP* activity in a cell; treatment of autoimmune disease by administering *UCP* activator; a composition of a *UCP* -inhibitor; therapy or prevention of infection using a *UCP*-inhibitor; nucleic acids encoding *UCP*; and transgenic animals and cells transfected with *UCP*. (106pp)

?

...completed examining records

S5 16 RD (unique items)
?show files;ds;t/3,k/all
File 5: Biosis Previews(R) 1969-2002/Dec W5
(c) 2002 BIOSIS
File 6: NTIS 1964-2003/Jan W1
(c) 2003 NTIS, Intl Cpyrght All Rights Res
File 34: SciSearch(R) Cited Ref Sci 1990-2002/Dec W5
(c) 2002 Inst for Sci Info
File 40: Enviroline(R) 1975-2002/Dec
File 50: CAB Abstracts 1972-2002/Nov
(c) 2002 CAB International
File 65: Inside Conferences 1993-2003/Jan W1
(c) 2003 BLDSC all rts. reserv.
File 68: Env. Bib. 1972-2002/Jun
(c) 2002 Internl Academy at Santa Barbara
File 71: ELSEVIER BIOBASE 1994-2003/Jan W1
(c) 2003 Elsevier Science B.V.
File 73: EMBASE 1974-2003/Dec W5
(c) 2003 Elsevier Science B.V.
File 94: JICST-EPlus 1985-2003/Oct W4
(c) 2003 Japan Science and Tech Corp (JST)
File 98: General Sci Abs/Full-Text 1984-2002/Nov
(c) 2002 The HW Wilson Co.
File 103: Energy SciTec 1974-2002/Dec B2
(c) 2002 Contains copyrighted material
File 143: Biol. & Agric. Index 1983-2002/Nov
(c) 2002 The HW Wilson Co
File 144: Pascal 1973-2002/Dec W4
(c) 2002 INIST/CNRS
File 155: MEDLINE(R) 1966-2002/Dec W5
File 156: ToxFile 1965-2002/Nov W3
(c) format only 2002 The Dialog Corporation
File 162: CAB Health 1983-2002/Nov
(c) 2002 CAB International
File 172: EMBASE Alert 2003/Jan W1
(c) 2003 Elsevier Science B.V.
File 305: Analytical Abstracts 1980-2002/Dec W2
(c) 2002 Royal Soc Chemistry
File 369: New Scientist 1994-2003/Dec W4
(c) 2003 Reed Business Information Ltd.
File 370: Science 1996-1999/Jul W3
(c) 1999 AAAS
File 399: CA SEARCH(R) 1967-2003/UD=13802
(c) 2003 American Chemical Society
File 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec
(c) 1998 Inst for Sci Info
File 8: Ei Compendex(R) 1970-2003/Dec W5
(c) 2003 Elsevier Eng. Info. Inc.
File 99: Wilson Appl. Sci & Tech Abs 1983-2002/Nov
(c) 2002 The HW Wilson Co.
File 135: NewsRx Weekly Reports 1995-2003/Dec W5
(c) 2003 NewsRx
File 266: FEDRIP 2002/Nov
Comp & dist by NTIS, Intl Copyright All Rights Res
File 315: ChemEng & Biotech Abs 1970-2003/Dec
(c) 2003 DECHEMA
File 357: Derwent Biotech Res. 1982-2003/Dec W5
(c) 2003 Thomson Derwent & ISI
File 358: Current BioTech Abs 1983-2003/Dec
(c) 2003 DECHEMA
File 35: Dissertation Abs Online 1861-2003/Dec
(c) 2003 ProQuest Info&Learning
File 48: SPORTDiscus 1962-2002/Dec
(c) 2002 Sport Information Resource Centre
File 91: MANTIS(TM) 1880-2002/Oct
2002 (c) Action Potential

File 149:TGG Health&Wellness (SM) 1976-2003/Dec W4
 (c) 2003 The Gale Group
 File 159:Cancerlit 1975-2002/Oct
 (c) format only 2002 Dialog Corporation
 File 164:Allied & Complementary Medicine 1984-2002/Dec
 (c) 2002 BLHCIS
 File 442:AMA Journals 1982-2003/Feb B1
 (c)2003 Amer Med Assn -FARS/DARS apply
 File 444:New England Journal of Med. 1985-2003/Jan W1
 (c) 2003 Mass. Med. Soc.
 File 467:ExtraMED(tm) 2000/Dec
 (c) 2001 Informania Ltd.

Set	Items	Description
S1	9073	(UNCOUPLING PROTEIN?) OR UCP OR UCP2
S2	5	S1 (S) LYSOSOM?
S3	3	RD (unique items)
S4	22	S1 AND LYSOSOM?
S5	16	RD (unique items)

>>>KWIC option is not available in file(s): 399

5/3,K/1 (Item 1 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2002 BIOSIS. All rts. reserv.

13787319 BIOSIS NO.: 200200416140

**Differentiation-dependent expression of cathepsin D and importance of
 lysosomal proteolysis in the degradation of UCP1 in brown adipocytes.**

AUTHOR: Moazed Banafsheh; Desautels M(a)
 AUTHOR ADDRESS: (a)College of Medicine, Department of Physiology,
 University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5E5**
 Canada E-Mail: desautel@duke.usask.ca
 JOURNAL: Canadian Journal of Physiology and Pharmacology 80 (6):p515-525
 June, 2002
 MEDIUM: print
 ISSN: 0008-4212
 DOCUMENT TYPE: Article
 RECORD TYPE: Abstract
 LANGUAGE: English

**Differentiation-dependent expression of cathepsin D and importance of
 lysosomal proteolysis in the degradation of UCP1 in brown adipocytes.**

ABSTRACT: The *lysosomal* protease cathepsin D increased markedly in brown adipocytes during differentiation in primary cultures. Differentiated cells had 20 times the amount of immunoreactive cathepsin D found...
 ...kinases (PI 3-kinase), previously shown to block formation of autophagic vacuoles. Thus, brown adipocytes acquire a large capacity for both uncoupled metabolism and for *lysosomal* proteolysis during differentiation. Withdrawal of NE, as often occurs in vivo from suppression of sympathetic nervous system activity, would not only terminate thermogenesis but also...

DESCRIPTORS:
 CHEMICALS & BIOCHEMICALS: ...*uncoupling protein 1*
 MISCELLANEOUS TERMS: *lysosomal* proteolysis

5/3,K/2 (Item 2 from file: 5)
 DIALOG(R)File 5:Biosis Previews(R)
 (c) 2002 BIOSIS. All rts. reserv.

09327235 BIOSIS NO.: 199497335605

**Temperature and phenylmethylsulfonyl fluoride sensitive loss of uncoupling
 protein in isolated brown adipose tissue mitochondrial membranes.**

AUTHOR: Desautels M; Dulos R A
 AUTHOR ADDRESS: Dep. Physiol., Coll. Med., Univ. Saskatchewan, Saskatoon,
 SK S7N 0W0**Canada

JOURNAL: Biochemistry and Cell Biology 72 (1-2):p1-7 1994
ISSN: 0829-8211
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English; French

ABSTRACT: When a membrane suspension prepared from isolated rat brown fat mitochondria was incubated at 37 degree C for 4 h, a loss of uncoupling protein (*UCP*) immunoreactivity was observed on Western blots. Analysis of (3H)GDP-binding characteristics to *UCP* in isolated membranes also showed a significant reduction in B-max without significant effect on K-d. The loss of *UCP* was not due to protease contamination from *lysosomes* or mast cell granules, since loss of *UCP* was still observed when mitochondria were treated with digitonin to lyse *lysosomes* prior to membrane preparation and when mitochondria were isolated from rats injected with compound 48/80 to degranulate mast cells. Furthermore, loss of *UCP* was observed at alkaline pH and was not affected by inhibitors of *lysosomal* enzymes. Loss of *UCP* immunoreactivity was markedly reduced when membranes were incubated at 4 degree C or in the presence of phenylmethylsulfonyl fluoride, but was not influenced by the...

...of GDP. Overall, these results indicate the presence of a serine protease within brown fat mitochondrial membranes that may be involved in the breakdown of *UCP*.

5/3,K/3 (Item 1 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2002 Inst for Sci Info. All rts. reserv.

07910272 Genuine Article#: 222WW No. References: 43
Title: Differentiation-dependent inhibition of proteolysis by norepinephrine in brown adipocytes
Author(s): Desautels M (REPRINT) ; Heal S
Corporate Source: UNIV SASKATCHEWAN, COLL MED, DEPT PHYSIOL/SASKATOON/SK S7N 5E5/CANADA/ (REPRINT)
Journal: AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1999 , V40, N2 (AUG), PE215-E222
ISSN: 0193-1849 Publication date: 19990800
Publisher: AMER PHYSIOLOGICAL SOC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814
Language: English Document Type: ARTICLE (ABSTRACT AVAILABLE)
...Identifiers--*UNCOUPLING PROTEIN THERMOGENIN; *ADIPOSE-TISSUE; FAT-CELLS; DEGRADATION; LEPTIN; EXPRESSION; MICE; AUTOPHAGY; MITOCHONDRIA; WHITE

5/3,K/4 (Item 2 from file: 34)
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci
(c) 2002 Inst for Sci Info. All rts. reserv.

04471827 Genuine Article#: TG447 No. References: 36
Title: MOLECULAR-CLONING, CHROMOSOMAL ASSIGNMENT, AND EXPRESSION OF THE MOUSE ASPARTYLGLUCOSAMINIDASE GENE
Author(s): TENHUNEN K; LAAN M; MANNINEN T; PALOTIE A; PELTONEN L; JALANKO A
Corporate Source: NATL PUBL HLTH INST, DEPT HUMAN MOLEC GENET, MANNERHEIMINTIE 166/SF-00300 HELSINKI//FINLAND/; NATL PUBL HLTH INST, DEPT HUMAN MOLEC GENET/SF-00300 HELSINKI//FINLAND/; UNIV HELSINKI, MEILAHTI HOSP, CENT HOSP, MOLEC GENET LAB/SF-00290 HELSINKI//FINLAND/
Journal: GENOMICS, 1995, V30, N2 (NOV 20), P244-250
ISSN: 0888-7543
Language: ENGLISH Document Type: ARTICLE (Abstract Available)

Abstract: Aspartylglucosaminidase (AGA) is a *lysosomal* enzyme, the deficiency of which leads to human *lysosomal* storage disease aspartylglucosaminuria. Here, we describe isolation, chromosomal

location, genomic structure, and tissue-specific expression of the mouse Aga gene as well as the intracellular...

...Identifiers--ENCODING HUMAN ASPARTYLGLUCOSAMINIDASE; LONG ARM;
*UNCOUPLING PROTEIN; *HYBRIDIZATION; GLYCOSYLASPARAGINASE; DELETION;
SUBUNITS; MUTATION; LINKAGE; COMPLEX

5/3,K/5 (Item 1 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

01650682 2001021402

Peroxisome proliferator-activated receptor alpha activates transcription of the brown fat uncoupling protein-1 gene. A link between regulation of the thermogenic and lipid oxidation pathways in the brown fat cell

Barbera M.J.; Schluter A.; Pedraza N.; Iglesias R.; Villarroja F.; Giralt M.

ADDRESS: M. Giralt, Dept. de Bioquímica Biologia Molec., Universitat de Barcelona, Avda Diagonal 645, E-08928-Barcelona, Spain

EMAIL: giralt@porthos.bio.ub.es

Journal: Journal of Biological Chemistry, 276/2 (1486-1493), 2001, United States

PUBLICATION DATE: January 12, 2001

CODEN: JBCHA

ISSN: 0021-9258

DOCUMENT TYPE: Article

LANGUAGES: English SUMMARY LANGUAGES: English

NO. OF REFERENCES: 55

...related to its high capacity of lipid oxidation. We analyzed the effects of PPARalpha activation on expression of the brown fat-specific uncoupling protein-1 (*ucp*-1) gene. Activators of PPARalpha increased *UCP*-1 mRNA levels severalfold both in primary brown adipocytes and in brown fat in vivo. Transient transfection assays indicated that the (-4551)UCP1-CAT construct, containing the 5prime-regulatory region of the rat *ucp*-1 gene, was activated by PPARalpha co-transfection in a dose-dependent manner and this activation was potentiated by Wy 14,643 and retinoid X receptor alpha. The coactivators CBP and PPARGamma-coactivator-1 (PGC-1), which is highly expressed in brown fat, also enhanced the PPARalphadependent regulation of the *ucp*-1 gene. Deletion and point-mutation mapping analysis indicated that the PPARalpha-responsive element was located in the upstream enhancer region of the *ucp*-1 gene. This -2485/-2458 element bound PPARalpha and PPARGamma from brown fat nuclei. Moreover, this element behaved as a promiscuous responsive site to either PPARalpha or PPARGamma activation, and we propose that it mediates *ucp*-1 gene up-regulation associated with adipogenic differentiation (via PPARGamma) or in coordination with gene expression for the fatty acid oxidation machinery required for active...

CLASSIFICATION CODE AND DESCRIPTION:

...*Lysosomes* and peroxisomes

5/3,K/6 (Item 2 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

01642076 2001014484

Role of leptin in peroxisome proliferator-activated receptor gamma coactivator-1 expression

Kakuma T.; Wang Z.-W.; Pan W.; Unger R.H.; Zhou Y.-T.

ADDRESS: Dr. R.H. Unger, Center for Diabetes Research, Texas Univ.

Southwestern Med. Center, 5323 Harry Hines Boulevard, Dallas, TX 75235-8854, United States

EMAIL: runger@mednet.swmed.edu

Journal: Endocrinology, 141/12 (4576-4582), 2000, United States

CODEN: ENDOA

ISSN: 0013-7227

DOCUMENT TYPE: Article
LANGUAGES: English SUMMARY LANGUAGES: English
NO. OF REFERENCES: 27

...coactivator-1 (PGC-1), a cold-induced protein expressed in brown adipose tissue (BAT), plays a role in adaptive thermogenesis by up-regulating uncoupling proteins (*UCP*). Here, we explore its relationship to the thermogenic actions of leptin, which also up-regulates UCPs. We find that PGC-1 messenger RNA (mRNA) is...

...days after induction of hyperleptinemia (>30 ng/ml) in Wistar rats, by adenovirus gene transfer, PGC-1 mRNA in BAT was 2.3-fold and *UCP*-1, 4-fold above controls. In isolated white adipocytes, PGC-1 mRNA increased 4.4-fold within 6 h of incubation with 20 ng/ml...

CLASSIFICATION CODE AND DESCRIPTION:
...*Lysosomes* and peroxisomes

5/3,K/7 (Item 3 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

01631624 2001004586

The effects of rexinoids and rosiglitazone on body weight and uncoupling protein isoform expression in the Zucker fa/fa rat

Emilsson V.; O'Dowd J.; Wang S.; Liu Y.-L.; Sennitt M.; Heyman R.; Cawthorne M.A.

ADDRESS: Dr. M.A. Cawthorne, Clore Laboratory, University of Buckingham, Hunter Street, Buckingham MK18 1EG, United Kingdom

Journal: Metabolism: Clinical and Experimental, 49/12 (1610-1615), 2000, United States

CODEN: META

ISSN: 0026-0495

DOCUMENT TYPE: Article
LANGUAGES: English SUMMARY LANGUAGES: English
NO. OF REFERENCES: 38

...action and improving glycemic control. In the present study, we compared the effects of rexinoids and a thiazolidinedione on body weight and mitochondrial uncoupling protein (*UCP*) isoform mRNA expression in the obese Zucker fa/fa rat. Long-term (2 weeks) oral treatment with the rexinoids LG100268 and LG100324 reduced food intake and body weight gain, whereas rosiglitazone (BRL49653) tended to increase both food intake and weight gain. LG100268 and LG100324 increased brown adipose tissue (BAT) *UCP*-1 mRNA content by 2.7-fold ($P < .002$) and 3.1-fold ($P < .001$), respectively, while BRL49653 had no effect on BAT *UCP*-1 mRNA content. Neither the rexinoids nor the thiazolidinedione had any effect on the level of mRNA encoding *UCP*-2 and the recently described PPARgamma coactivator-1 (PGC-1). LG100324 increased *UCP*-3 mRNA content by 3.6-fold ($P < .0005$) in muscle and 4.3-fold ($P < .0002$) in white adipose tissue (WAT). LG100268 increased *UCP*-3 mRNA content in WAT by 2-fold ($P < .005$) but was without any effect on muscle *UCP*-3. BRL49653 increased *UCP*-3 mRNA content by 2.1-fold ($P < .005$) in muscle and 2.7-fold ($P < .003$) in WAT. Thus, the rexinoids, but not the thiazolidinedione, have an antiobesity action by reducing food intake, and the increase in *UCP*-1 mRNA content in BAT may reflect a stimulation of BAT *UCP*-1 activity. Copyright (c) 2000 by W.B. Saunders Company.

CLASSIFICATION CODE AND DESCRIPTION:
...*Lysosomes* and peroxisomes

5/3,K/8 (Item 4 from file: 71)
DIALOG(R)File 71:ELSEVIER BIOBASE
(c) 2003 Elsevier Science B.V. All rts. reserv.

01588003 2000247769

Down-regulation of uncoupling protein-3 and -2 by thiazolidinediones in C2C12 myotubes

Cabrero A.; Alegret M.; Sanchez R.M.; Adzet T.; Laguna J.C.; Vazquez M.
ADDRESS: M. Vazquez, Unidad de Farmacologia, Depto. de Farmacol. Quim.
Terap., Universidad de Barcelona, Diagonal 643, E-08028 Barcelona
, Spain

EMAIL: mvaz@farmacia.far.ub.es

Journal: FEBS Letters, 484/1 (37-42), 2000, Netherlands

PUBLICATION DATE: October 27, 2000

CODEN: FEBLA

ISSN: 0014-5793

PUBLISHER ITEM IDENTIFIER: S0014579300021256

DOCUMENT TYPE: Article

LANGUAGES: English SUMMARY LANGUAGES: English

NO. OF REFERENCES: 41

...from oxidative phosphorylation by dissipating the proton gradient across the membrane. We studied the direct effect of several peroxisome proliferator-activated receptor (PPAR) ligands on *UCP*-3 and *UCP*-2 mRNA expression in C2C12 myotubes for 24 h. In the absence of exogenous fatty acids, treatment of C2C12 cells with a selective PPARalpha activator (Wy-14,643) or a non-selective PPAR activator (bezafibrate) did not affect the expression of *UCP*-3 mRNA levels, whereas *UCP*-2 expression was slightly increased. In contrast, troglitazone, a thiazolidinedione which selectively activates PPARgamma, strongly decreased *UCP*-3 and *UCP*-2 mRNA levels. Another thiazolidinedione, ciglitazone, had the same effect, but to a lower extent, suggesting that PPARgamma activation is involved. Further, the presence of 0.5 mM oleic acid strongly increased *UCP*-3 mRNA levels and troglitazone addition failed to block the effect of this fatty acid. The drop in *UCP* expression after thiazolidinedione treatment correlated well with a reduction in PPARalpha mRNA levels produced by this drug, linking the reduction in PPARalpha mRNA levels with the down-regulation of *UCP* mRNA in C2C12 myotubes after thiazolidinedione treatment. (C) 2000 Federation of European Biochemical Societies.

DESCRIPTORS:

UCP; PPAR; Thiazolidinedione; Troglitazone; Ciglitazone; C2C12

CLASSIFICATION CODE AND DESCRIPTION:

...*Lysosomes* and peroxisomes

5/3,K/9 (Item 5 from file: 71)

DIALOG(R)File 71:ELSEVIER BIOBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

01518187

2000197051

Peroxisome proliferator-activated receptor alpha (PPARalpha) activators, bezafibrate and Wy-14,643, increase uncoupling protein-3 mRNA levels without modifying the mitochondrial membrane potential in primary culture of rat preadipocytes

Cabrero A.; Alegret M.; Sanchez R.; Adzet T.; Laguna J.C.; Vazquez M.

ADDRESS: M. Vazquez, Unidad de Farmacologia, Facultad de Farmacia, Diagonal 643, E-08028 Barcelona, Spain

EMAIL: mvaz@farmacia.far.ub.es

Journal: Archives of Biochemistry and Biophysics, 380/2 (353-359), 2000, United States

PUBLICATION DATE: August 15, 2000

CODEN: ABBIA

ISSN: 0003-9861

DOCUMENT TYPE: Article

LANGUAGES: English SUMMARY LANGUAGES: English

NO. OF REFERENCES: 36

...that develops during mitochondrial respiration at the expense of ATP synthesis. We have studied the effects of two fibrates, bezafibrate and Wy-14,643, on *UCP*-3 and *UCP*-2 mRNA levels in primary monolayer cultures

of rat adipocytes and undifferentiated preadipocytes. Treatment with both PPARalpha activators for 24 h up-regulated *UCP*-3 mRNA levels. Thus, bezafibrate treatment resulted in an 8-fold induction in *UCP*-3 mRNA levels in preadipocytes compared with the 3.5-fold induction observed in adipocytes. Differences in the induction of *UCP*-3 between these cells correlated well with the higher expression of PPARalpha and RXRalpha mRNA values in preadipocytes compared to adipocytes. Wy-14,643 caused similar effects on *UCP*-3 mRNA expression. In contrast to *UCP*-3, *UCP*-2 mRNA levels were only slightly modified by bezafibrate in adipocytes. The induction in *UCP*-3 expression was not accompanied by changes in the mitochondrial membrane potential of rat primary preadipocytes after bezafibrate or Wy-14,643 treatment. Since it has been proposed that *UCP*-3 could be involved in the regulation of the use of fatty acids as fuel substrates, the *UCP*-3 induction achieved after bezafibrate and Wy-14,643 treatment may indicate a higher oxidation of fatty acids, limiting their availability to be stored as...

DESCRIPTORS:

UCP-3; Bezafibrate; Wy-14,643; PPARalpha; Preadipocyte

CLASSIFICATION CODE AND DESCRIPTION:

...*Lysosomes* and peroxisomes

89.1.8.7 - CELL AND DEVELOPMENTAL BIOLOGY

5/3,K/10 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2003 Elsevier Science B.V. All rts. reserv.

10997864 EMBASE No: 2001043384

The interaction of tributyllead with *lysosomes* from rat liver

Bragadin M.; Marton D.; Manente S.; Toninello A.

M. Bragadin, Dipartimento Scienze Ambientali, Universita di Venezia,
30123 Venezia Italy

AUTHOR EMAIL: bragadin@unive.it

Journal of Inorganic Biochemistry (J. INORG. BIOCHEM.) (United States)

15 JAN 2001, 83/2-3 (229-232)

CODEN: JIBID ISSN: 0162-0134

PUBLISHER ITEM IDENTIFIER: S0162013400001951

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 27

The interaction of tributyllead with *lysosomes* from rat liver

The interactions of tributyllead with *lysosomes* from rat liver have been studied. It results that the organometal compound induces a fast alkalinization in energized *lysosomes*. The interpretation is that the compound is a potent proton carrier. This function could explain the toxicity, in particular at neurological level of the compound...

DRUG DESCRIPTORS:

uncoupling protein; bafilomycin; carbonyl cyanide 4

(trifluoromethoxy)phenylhydrazine; acridine orange; proton pump;

valinomycin; duramycin; unclassified drug

MEDICAL DESCRIPTORS:

*liver *lysosome*; *molecular interaction

5/3,K/11 (Item 1 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2003 American Chemical Society. All rts. reserv.

136035750 CA: 136(3)35750y JOURNAL

Effects of leptin deficiency and short-term repletion on hepatic gene expression in genetically obese mice

AUTHOR(S): Ferrante, Anthony W., Jr.; Thearle, Marie; Liao, Ted; Leibel, Rudolph L.

LOCATION: Department of Medicine, Naomi Berrie Diabetes Center, Columbia University College of Physicians and Surgeons, New York, NY, 10032, USA
JOURNAL: Diabetes (Diabetes) DATE: 2001 VOLUME: 50 NUMBER: 10 PAGES: 2268-2278 CODEN: DIAEAZ ISSN: 0012-1797 LANGUAGE: English PUBLISHER: American Diabetes Association

5/3,K/12 (Item 2 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

134365172 CA: 134(26)365172t JOURNAL
Gene expression profile in Alzheimer's brain screened by molecular indexing
AUTHOR(S): Doyu, M.; Sawada, K.-i.; Mitsuma, N.; Niwa, J.-i.; Yoshimoto, M.; Fujii, Y.; Sobue, G.; Kato, K.
LOCATION: Department of Neurology, Nagoya University School of Medicine, Syowa, Nagoya, Japan, 466-8550
JOURNAL: Mol. Brain Res. DATE: 2001 VOLUME: 87 NUMBER: 1 PAGES: 1-11
CODEN: MBREE4 ISSN: 0169-328X PUBLISHER ITEM IDENTIFIER: 0169-328X(00)00223-0 LANGUAGE: English PUBLISHER: Elsevier Science B.V.

5/3,K/13 (Item 3 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

134069876 CA: 134(6)69876t PATENT
Subcellular distribution of uncoupling proteins as a marker of cell proliferation capacity and its manipulation in tumor therapy
INVENTOR(AUTHOR): Newell, Martha K.
LOCATION: USA
ASSIGNEE: University of Vermont and State Agricultural College
PATENT: PCT International ; WO 200078941 A2 DATE: 20001228
APPLICATION: WO 2000US17245 (20000622) *US PV140574 (19990623)
PAGES: 106 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C12N-015/00A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ; UG; UZ; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG

5/3,K/14 (Item 4 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2003 American Chemical Society. All rts. reserv.

134028172 CA: 134(3)28172s JOURNAL
The expression of adipogenic genes is decreased in obesity and diabetes mellitus
AUTHOR(S): Nadler, Samuel T.; Stoeher, Jonathan P.; Schueler, Kathryn L.; Tanimoto, Gene; Yandell, Brian S.; Attie, Alan D.
LOCATION: Department of Biochemistry, University of Wisconsin, Madison, WI, 53706, USA
JOURNAL: Proc. Natl. Acad. Sci. U. S. A. DATE: 2000 VOLUME: 97
NUMBER: 21 PAGES: 11371-11376 CODEN: PNASA6 ISSN: 0027-8424
LANGUAGE: English PUBLISHER: National Academy of Sciences

5/3,K/15 (Item 1 from file: 357)
DIALOG(R)File 357:Derwent Biotech Res.
(c) 2003 Thomson Derwent & ISI. All rts. reserv.

0265635 DBR Accession No.: 2001-05389 PATENT

Inhibiting plasma membrane uncoupling protein expression in tumor cells and rapidly dividing bacterial cells, for treating cancer and infectious diseases - uncoupling protein-inhibitor drug, screening for chemotherapy sensitization of tumor cell

AUTHOR: Newell M K

CORPORATE SOURCE: Burlington, VT, USA.

PATENT ASSIGNEE: Univ.Vermont 2000

PATENT NUMBER: WO 200078941 PATENT DATE: 20001228 WPI ACCESSION NO.:
2001-102716 (2011)

PRIORITY APPLIC. NO.: US 140574 APPLIC. DATE: 19990623

NATIONAL APPLIC. NO.: WO 2000US17245 APPLIC. DATE: 20000622

LANGUAGE: English

ABSTRACT: Inhibiting plasma membrane uncoupling protein (*UCP*) expression in a cell, comprises contacting a cell with a plasma membrane *UCP* -inhibitor. Also new are: a composition of a plasma membrane targeted *UCP* -inhibitor; sensitizing a resistant tumor cell to a cytotoxic therapy by expressing a functional *UCP* or *UCP* fragment in a plasma membrane of a resistant tumor cell to sensitize the resistant tumor cell to a cytotoxic therapeutic; screening a tumor cell for...

... for screening a tumor cell or a subject for susceptibility to treatment with a chemotherapeutic agent; inducing cellular division in a growth arrested cell; regulating *lysosomal* pH by modifying *lysosomal* *UCP* activity in a cell; treatment of autoimmune disease by administering *UCP* activator; a composition of a *UCP* -inhibitor; therapy or prevention of infection using a *UCP*-inhibitor; nucleic acids encoding *UCP*; and transgenic animals and cells transfected with *UCP*. (106pp)

5/3,K/16 (Item 1 from file: 149)

DIALOG(R)File 149:TGG Health&Wellness DB(SM)

(c) 2003 The Gale Group. All rts. reserv.

02084876 SUPPLIER NUMBER: 87103154 (USE FORMAT 7 OR 9 FOR FULL TEXT)

Something for everyone: the WCD conference program.(World Congress and Exposition on Disabilities)

The Exceptional Parent, 32, 5, 42(2)

May,

2002

PUBLICATION FORMAT: Magazine/Journal ISSN: 0046-9157 LANGUAGE: English

RECORD TYPE: Fulltext TARGET AUDIENCE: Consumer

WORD COUNT: 789 LINE COUNT: 00191

... Alliance of Direct
Support Professionals (NADSP)
* The Spectrum of Rare
Disorders
* Dolphins and the Disabled
* Universal Newborn Screening:
Screening Methodologies
* Women, Pregnancy and Epilepsy
Peroxisomal, *Lysosomal* and
Mitochondrial Disorders
* Legislation, Conformity, And
Outcomes For People With
Disabilities
* Inclusive Outdoor Education
Programs for Students with
Special Needs Part I
* Adaptive Snow Skiing...Foundation
The Center for Discovery
The Disability Resource
The Hali Project
The Liberty Motor Co.
The National
Neurofibromatosis
Foundation, Inc.

Theradapt
Today's Caregiver Magazine
UCP (United Cerebral Palsy)
United Parents' Syndicate
on Disabilities
U.S. Customs Service
U.S. Department of Justice
U.S. Disabled Athletes Fund
Vail Products, Inc...

?